ONLY FOR PALLIATIVE THERAPY OF REFRACTORY OVARIAN CANCER.
ADULTS
PO 260 MG/M 2 /DAY FOR 14 OR 21 DAYS IN A 28-DAY CYCLE, GIVEN IN 4?DIVIDED DOSES (ROUND DOSE TO THE NEAREST 50 MG) AFTER MEALS AND AT BEDTIME (USUAL DOSE, 400?MG/DAY). DISCONTINUE THERAPY FOR AT LEAST 14?DAYS AND RESUME AT 200 MG/M 2 /DAY IN ANY OF THE FOLLOWING SITUATIONS:
TREATMENT-RESISTANT GI ADVERSE EFFECTS; WBC LESS THAN 2,000/MM 3 ; GRANULOCYTE COUNT LESS THAN 1,000/MM 3 ; PLATELET COUNT LESS THAN 75,000/MM 3 ; PROGRESSIVE NEUROTOXICITY. DISCONTINUE PERMANENTLY IF NEUROLOGIC SYMPTOMS PERSIST AFTER DOSE REDUCTION.